Syndax Pharmaceuticals
SNDX
97 hedge funds and large institutions have $484M invested in Syndax Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 13 reducing their positions, and 15 closing their positions.
372% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $2.79M
262% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 13
112% more capital invested
Capital invested by funds: $228M → $484M (+$256M)
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
21.76% more ownership
Funds ownership: 68.68% → 90.44% (+22%)
17% more funds holding
Funds holding: 83 → 97 (+14)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$23.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$23.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$15.7M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$15.6M |
| 5 |
O
OrbiMed
New York
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$5.98M |
| 2 |
BlackRock
New York
|
-$4.05M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$990K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$891K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$867K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
101
Soleus Capital Management
Greenwich,
Connecticut
| – | -$230K | -20,980 | Closed |
|
|
CANY
102
Caxton Associates (New York)
New York
| – | -$223K | -20,326 | Closed |
|
103
Acadian Asset Management
Boston,
Massachusetts
| – | -$135K | -12,301 | Closed |
|
|
PP
104
PDT Partners
New York
| – | -$134K | -12,200 | Closed |
|
105
VOYA Investment Management
Atlanta,
Georgia
| – | -$126K | -11,528 | Closed |
|
106
Victory Capital Management
San Antonio,
Texas
| – | -$94K | -8,572 | Closed |
|
107
Osaic Holdings
Scottsdale,
Arizona
| – | -$22K | -2,000 | Closed |
|
|
MAM
108
Meeder Asset Management
Dublin,
Ohio
| – | -$13.7K | -901 | -94% |
|
|
DWA
109
Dorsey Wright & Associates
Pasadena,
California
| – | -$9K | -803 | Closed |
|
|
GWM
110
Geneos Wealth Management
Englewood,
Colorado
| – | -$4K | -470 | Closed |
|
|
FDCDDQ
111
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$2.74K | -250 | Closed |
|
112
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | -67 | Closed |
|
SNDX Hedge Fund Activity: Q2 2020 in Review
97 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2020, worth a combined $484M — up 112% from $228M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new SNDX positions and 15 closed out — a net gain of 14 holders — while 47 added to existing stakes and 13 trimmed.
The largest buyer was Boxer Capital, adding an estimated $23.8M. The largest seller was Renaissance Technologies, cutting an estimated $5.98M.
- 97 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2020, up from 83 in Q1 2020.
- Funds reported $484M of Syndax Pharmaceuticals stock for Q2 2020, up 112% quarter-over-quarter.
- 29 funds opened new Syndax Pharmaceuticals positions in Q2 2020 and 15 closed out, a net change of +14 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2020 was Boxer Capital, an estimated $23.8M added.
- The largest Syndax Pharmaceuticals seller in Q2 2020 was Renaissance Technologies, an estimated $5.98M sold.
Based on aggregated 13F filings for Q2 2020.